FDA issued a complete response letter for UX111, and Bank of America reiterated a Buy rating for Ultragenyx Pharmaceutical.
2 reports, 2 independent
Updated Aug 9
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA issued a complete response letter for UX111, and Bank of America reiterated a Buy rating for Ultragenyx Pharmaceutical.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
- FDA
-
Ultragenyx Pharmaceutical
biopharmaceutical company based in Novato, California, United States
Nothing else this week.
Related events
- The FDA issued a Complete Response Letter regarding the RP1 BLA to Replimune Group, Inc. on August 7, 2025.
- Biocon's subsidiary received FDA approval for a drug in the United States on August 18, 2026.
- A product was launched in the U.S. market following FDA involvement.
- Amylyx Pharmaceuticals is seeking FDA approval for a new drug treatment.
- BioXcel Therapeutics received FDA approval for its drug and announced results from New Haven.
Coverage
Newest first; wire copies grouped- yahoo.com
- Insider MonkeyBank of America Securities Reiterated a Buy Rating on Ultragenyx Pharmaceutical (RARE) Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is one of the Best 52-Week Low Stocks to Buy According to Analysts.